(Q37155592)

English

Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer

scientific article published on 15 December 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Pamela J Atherton

8

object named as

Pamela J Atherton

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

10

object named as

Edith A Perez

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

Stephanie L Hines

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Betty Anne Mincey

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jeff A Sloan

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sachdev P Thomas

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Elaine Chottiner

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Charles L Loprinzi

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Mark D Carlson

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Muhammad Salim

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

15 December 2008

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

27

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1047-1053

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Cathepsin K inhibitors: a novel target for osteoporosis therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667810

6 September 2017

Denosumab in postmenopausal women with low bone mineral density

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667810

6 September 2017

Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667810

6 September 2017

Risedronate: a clinical review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667810

6 September 2017

A high incidence of vertebral fracture in women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667810

6 September 2017

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667810

6 September 2017

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667810

29 September 2017

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667810

3 September 2018

Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667810

3 September 2018

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667810

3 September 2018

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19075260

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19075260

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19075260

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19075260

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19075260

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19075260

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19075260

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.19.1783

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37155592&oldid=2149890497"